

# Exhaled nitric oxide in children with asthma:

- 1) Outdoor- versus indoor-generated PM
- 2) Short term PM exposure

Therese Mar, Ryan Allen, Karen  
Jansen, Jane Koenig, Timothy Larson,  
Thomas Lumley, Sally Liu  
University of Washington

# Background

- Exhaled nitric oxide (eNO) is a ubiquitous molecule in the body and is a non-invasive marker of airway inflammation
- eNO is known to be elevated in individuals with asthma, is increased when a subject is having an asthma attack, and is decreased in those individuals using corticosteroid medication
- eNO has been compared with other techniques for measuring inflammation (ex. breath condensate, induced sputum)

# Subject Characteristics



- 19 subjects: 14 male, 5 female
- Ages 6-13
- Medication use:
  - 10 inhaled corticosteroid (ICS) users
  - 9 ICS nonusers
- FEV1%: 67-100%

# Data Collection

## PM<sub>2.5</sub>

- Local outdoor (HI)
- Local indoor (HI)
- Personal (HPEM)
- Average of 3 central sites: Kent, Lynnwood, and Lake Forest Park (TEOM)

## Health Endpoint

- Daily concentration of eNO (ppb)



# Estimating Exposure to Ambient and Non-ambient PM

# Source-Specific Exposure Model

$$E_t = E_a + E_{ig} + \text{“personal cloud”}$$

$$E_t = \text{HPEM or pDR}$$
$$E_a = \underbrace{[y + (1-y)(F_{inf})]}_{\alpha = \text{“attenuation factor”}} C_a$$
$$E_{ig} = (1-y)(C_{ig})$$

$y$  = fraction of time spent outdoors

$C_a$  = ambient (outdoor) concentration (HI or neph)

$C_{ig}$  = indoor-generated concentration =  $C_i - C_a(F_{inf})$

$C_i$  = indoor concentration (HI or neph)

# Results

- Associations between various measured PM metrics and exhaled NO
- Associations between estimated concentrations of outdoor- and indoor-generated PM<sub>2.5</sub> and eNO

# Results ICS nonusers

## eNO, ppb (95% CI)

For a 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{PM}_{2.5}$ , eNO increase

- Personal: 4.5 (1.02, 7.9)
- Indoor: 4.2 (1.02, 7.4)
- Outdoor : 4.3 (1.4, 7.2)
- Central: 4.2 (1.2, 6.4)
- EIG: -3.3 (-1.1, 7.7)
- EAG: 5.0 (0.3, 9.7)

– No effects were seen in ICS users



# Previous findings

- Exhaled NO is a feasible, non-invasive technique for measuring airway inflammation
- Various measures of PM<sub>2.5</sub> were associated with a marker of airway inflammation in children with asthma
- Inhaled corticosteroid use attenuated the association between eNO and PM<sub>2.5</sub>
- Other panel studies have reported associations between PM<sub>2.5</sub> and eNO. (Adamkiewicz et al, 2004; Jansen et al, 2004)

# Short term analysis

- **Objectives:**
- To determine the effect of short term PM exposure (hourly lags) on exhaled nitric oxide

# Methods

- Polynomial distributed lag model
- Hourly lags of PM up to 48 hours
- Model controlled for temperature, relative humidity, ambient NO concentrations and medication use

# Polynomial distributed lag model

$$\begin{aligned} E[Y] = & B_0 + b_i + B_1(Z1_{ids} - \overline{Z1_{is}}) + B_2 med_i + B_3 med_i * (Z1_{ids} - \overline{Z1_{is}}) \\ & + B_4(Z2_{ids} - \overline{Z2_{is}}) + B_5 med_i * (Z2_{ids} - \overline{Z2_{is}}) + B_6(Z3_{ids} - \overline{Z3_{is}}) \\ & + B_7 med_i * (Z3_{ids} - \overline{Z3_{is}}) + B_8(Z4_{ids} - \overline{Z4_{is}}) + B_9 med_i * (Z4_{ids} - \overline{Z4_{is}}) \\ & + B_{10}(W_{ids} - \overline{W_{is}}) + B_{11} age + B_{12} rh + B_{13} temp \end{aligned}$$

where


$$Z1 = \sum_{n=1}^{24} PMlag_n, \quad Z2 = \sum_{n=1}^{24} n * PMlag_n, \quad Z3 = \sum_{n=1}^{24} n^2 * PMlag_n \quad \text{and} \quad Z4 = \sum_{n=1}^{24} n^3 * PMlag_n$$

W is the ambient NO concentration

# Averaged PM effect

PM	change in eNO per 10 $\mu\text{g}/\text{m}^3$ PM	95% Lower CI	95% Upper CI
lag 1 hour	7.16	3.72	10.59
lag 4 hour	6.39	2.85	9.93
lag 8 hour	0.56	-1.07	2.20
PM 2.5 averaged from 7pm to 4 am	1.61	0.15	3.07
PM 10 averaged from 7 pm to 4 am	2.27	0.78	3.77

# effect of lags on eNO



# Conclusions

- eNO is associated with PM exposure up to 11 hours prior to eNO measurement
- An association between eNO and PM averaged during high wood smoke hours (7 pm to 4 am) was observed